Altered expression of apoA-I, apoA-IV and PON-1 activity in CBS deficient homocystinuria in the presence and absence of treatment: Possible implications for cardiovascular outcomes

Molecular Genetics and Metabolism

Volumn 107, Issue 1-2, 2012, Pages 55-65

  Jiang, Hua ^a   Stabler, Sally P ^b   Allen, Robert H ^b   MacLean, Kenneth N ^a  

^a Children's Hospital Colorado   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

ApoA I; ApoA IV; Cystathionine beta synthase; Homocysteine; Homocystinuria; Paraoxonase 1

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; ARYLDIALKYLPHOSPHATASE 1; BETAINE; CYSTATHIONINE BETA SYNTHASE; CYSTINE; HOMOCYSTEINE;

ADD ON THERAPY; ADOLESCENT; ADULT; AMINO ACID BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CHILD; COGNITIVE DEFECT; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HOMOCYSTINURIA; HUMAN; HUMAN TISSUE; LIPOPROTEIN BLOOD LEVEL; MALE; MOUSE; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN RESTRICTION; SCHOOL CHILD;

ADOLESCENT; ADULT; ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS A; ARYLDIALKYLPHOSPHATASE; BETAINE; BRAIN; CARBOXYLIC ESTER HYDROLASES; CHILD; CHILD, PRESCHOOL; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; HOMOCYSTEINE; HOMOCYSTINURIA; HUMANS; LIPOTROPIC AGENTS; LIVER; MALE; MICE; MICE, KNOCKOUT; YOUNG ADULT;

MUS;

EID: 84866160754     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2012.04.025     Document Type: Article

References (70)

1. Mudd S.H., Levy H.L., Kraus J.P. Disorders of transsulfuration. The Metabolic and Molecular Bases of Inherited Disease 2001, 2007-2056. McGraw-Hill, New York. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle, B. Childs, K. Kinzler, B. Vogelstein (Eds.).
2. Wilcken D.E., Wilcken B., Dudman N.P., Tyrrell P.A. Homocystinuria-the effects of betaine in the treatment of patients not responsive to pyridoxine. N. Engl. J. Med. 1983, 309:448-453.
3. Mudd S.H., Skovby F., Levy H.L., Pettigrew K.D., Wilcken B., Pyeritz R.E., Andria G., Boers G.H.J., Bromberg I.L., Cerone R., Fowler B., Grobe H., Schmidt H., Schweitzer L. The natural history of homocystinuria due to cystathionine b-synthase deficiency. Am. J. Hum. Genet. 1985, 37:1-31.
4. Watanabe M., Osada J., Aratani Y., Kluckman K., Reddick R., Malinow M.R., Maeda N. Mice deficient in cystathionine beta-synthase: animal models for mild and severe homocyst(e)inemia. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:1585-1589.
5. Maclean K.N., Sikora J., Kozich V., Jiang H., Greiner L.S., Kraus E., Krijt J., Crnic L.S., Allen R.H., Stabler S.P., Elleder M., Kraus J.P. Cystathionine beta-synthase null homocystinuric mice fail to exhibit altered hemostasis or lowering of plasma homocysteine in response to betaine treatment. Mol. Genet. Metab. 2010, 101:163-171.
6. Maclean K.N., Sikora J., Kozich V., Jiang H., Greiner L.S., Kraus E., Krijt J., Overdier K.H., Collard R., Brodsky G.L., Meltesen L., Crnic L.S., Allen R.H., Stabler S.P., Elleder M., Rozen R., Patterson D., Kraus J.P. A novel transgenic mouse model of CBS-deficient homocystinuria does not incur hepatic steatosis or fibrosis and exhibits a hypercoagulative phenotype that is ameliorated by betaine treatment. Mol. Genet. Metab. 2010, 101:153-162.
7. Maclean K.N., Jiang H., Greiner L.S., Allen R.H., Stabler S.P. Long-term betaine therapy in a murine model of cystathionine beta-synthase deficient homocystinuria: decreased efficacy over time reveals a significant threshold effect between elevated homocysteine and thrombotic risk. Mol. Genet. Metab. 2012, 105:395-403.
8. Keating A.K., Freehauf C., Jiang H., Brodsky G.L., Stabler S.P., Allen R.H., Graham D.K., Thomas J.A., Van Hove J.L., Maclean K.N. Constitutive induction of pro-inflammatory and chemotactic cytokines in cystathionine beta-synthase deficient homocystinuria. Mol. Genet. Metab. 2011, 103:330-337.
9. Mackness M.I., Mackness B., Durrington P.N., Connelly P.W., Hegele R.A. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr. Opin. Lipidol. 1996, 7:69-76.
10. Janel N., Robert K., Chabert C., Ledru A., Gouedard C., Barouki R., Delabar J.M., Chasse J.F. Mouse liver paraoxonase-1 gene expression is downregulated in hyperhomocysteinemia. Thromb. Haemost. 2004, 92:221-222.
11. Lewis T.L., Cao D., Lu H., Mans R.A., Su Y.R., Jungbauer L., Linton M.F., Fazio S., LaDu M.J., Li L. Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease. J. Biol. Chem. 2010, 285:36958-36968.
12. Mikael L.G., Genest J., Rozen R. Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease. Circ. Res. 2006, 98:564-571.
13. Liao D., Tan H., Hui R., Li Z., Jiang X., Gaubatz J., Yang F., Durante W., Chan L., Schafer A.I., Pownall H.J., Yang X., Wang H. Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I Protein synthesis and enhancing HDL cholesterol clearance. Circ. Res. 2006, 99:598-606.
14. Nuno-Ayala M., Guillen N., Navarro M.A., Lou-Bonafonte J.M., Arnal C., Gascon S., Barranquero C., Godino J., Royo-Canas M., Sarria A.J., Guzman M.A., Hernandez E., Bregante M.A., Garcia-Gimeno M.A., Osada J. Cysteinemia, rather than homocysteinemia, is associated with plasma apolipoprotein A-I levels in hyperhomocysteinemia: lipid metabolism in cystathionine beta-synthase deficiency. Atherosclerosis 2010, 212:268-273.
15. Wilcox H.G., Kenagy R., Weinstein I., Heimberg M. Alterations of plasma HDL lipids and apolipoproteins in female rats treated with ethynyl estradiol. Biochim. Biophys. Acta 1981, 666:348-355.
16. Bergmeyer H.U., Horder M. International federation of clinical chemistry. Scientific committee. Expert panel on enzymes. IFCC document stage 2, draft 1; 1979-11-19 with a view to an IFCC recommendation. IFCC methods for the measurement of catalytic concentration of enzymes. Part 3. IFCC method for alanine aminotransferase. J. Clin. Chem. Clin. Biochem. 1980, 18:521-534.
17. Allen R.H., Stabler S.P., Lindenbaum J. Serum betaine, N,N-dimethylglycine and N-methylglycine levels in patients with cobalamin and folate deficiency and related inborn errors of metabolism. Metabolism 1993, 42:1448-1460.
18. Stabler S.P., Allen R.H. Quantification of serum and urinary s-adenosylmethionine and s-adenosylhomocysteine by stable-isotope-dilution liquid chromatography-mass spectrometry. Clin. Chem. 2004, 50:365-372.
19. Gan K.N., Smolen A., Eckerson H.W., La Du B.N. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab. Dispos. 1991, 19:100-106.
20. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
21. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
22. Robert K., Chasse J.F., Santiard-Baron D., Vayssettes C., Chabli A., Aupetit J., Maeda N., Kamoun P., London J., Janel N. Altered gene expression in liver from a murine model of hyperhomocysteinemia. J. Biol. Chem. 2003, 278:31504-31511.
23. Durrington P.N., Mackness B., Mackness M.I. Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2001, 21:473-480.
24. Shih D.M., Gu L., Xia Y.R., Navab M., Li W.F., Hama S., Castellani L.W., Furlong C.E., Costa L.G., Fogelman A.M., Lusis A.J. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 1998, 394:284-287.
25. Lusis A.J. Atherosclerosis. Nature 2000, 407:233-241.
26. Kontush A., Chapman M.J. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol. Rev. 2006, 58:342-374.
27. Navab M., Ananthramaiah G.M., Reddy S.T., Van Lenten B.J., Ansell B.J., Fonarow G.C., Vahabzadeh K., Hama S., Hough G., Kamranpour N., Berliner J.A., Lusis A.J., Fogelman A.M. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J. Lipid Res. 2004, 45:993-1007.
28. Saito H., Lund-Katz S., Phillips M.C. Contributions of domain structure and lipid interaction to the functionality of exchangeable human apolipoproteins. Prog. Lipid Res. 2004, 43:350-380.
29. Wong W.M., Gerry A.B., Putt W., Roberts J.L., Weinberg R.B., Humphries S.E., Leake D.S., Talmud P.J. Common variants of apolipoprotein A-IV differ in their ability to inhibit low density lipoprotein oxidation. Atherosclerosis 2007, 192:266-274.
30. Elliott D.A., Weickert C.S., Garner B. Apolipoproteins in the brain: implications for neurological and psychiatric disorders. Clin. Lipidol. 2010, 51:555-573.
31. Dietschy J.M., Turley S.D. Cholesterol metabolism in the brain. Curr. Opin. Lipidol. 2001, 12:105-112.
32. Selhub J. Mild hyperhomocysteinemia and arterial occlusive disease. Haematologica 1997, 82:129-132.
33. D'Angelo A., Selhub J. Homocysteine and thrombotic disease. Blood 1997, 90:1-11.
34. Voetsch B., Loscalzo J. Genetic determinants of arterial thrombosis. Arterioscler. Thromb. Vasc. Biol. 2004, 24:216-229.
35. Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 1995, 96:2882-2891.
36. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., La Du B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J. Clin. Invest. 1998, 101:1581-1590.
37. Perla-Kajan J., Jakubowski H. Paraoxonase 1 protects against protein N-homocysteinylation in humans. FASEB J. 2010, 24:931-936.
38. Jakubowski H. The role of paraoxonase 1 in the detoxification of homocysteine thiolactone. Adv. Exp. Med. Biol. 2010, 660:113-127.
39. Ferre N., Marsillach J., Camps J., Mackness B., Mackness M., Riu F., Coll B., Tous M., Joven J. Paraoxonase-1 is associated with oxidative stress, fibrosis and FAS expression in chronic liver diseases. J. Hepatol. 2006, 45:51-59.
40. Rubin E.M., Krauss R.M., Spangler E.A., Verstuyft J.G., Clift S.M. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 1991, 353:265-267.
41. Suc I., Escargueil-Blanc I., Troly M., Salvayre R., Negre-Salvayre A. HDL and ApoA prevent cell death of endothelial cells induced by oxidized LDL. Arterioscler. Thromb. Vasc. Biol. 1997, 17:2158-2166.
42. Cockerill G.W., Rye K.A., Gamble J.R., Vadas M.A., Barter P.J. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler. Thromb. Vasc. Biol. 1995, 15:1987-1994.
43. Ho Y.K., Brown M.S., Goldstein J.L. Hydrolysis and excretion of cytoplasmic cholesteryl esters by macrophages: stimulation by high density lipoprotein and other agents. J. Lipid Res. 1980, 21:391-398.
44. Eichinger S., Pecheniuk N.M., Hron G., Deguchi H., Schemper M., Kyrle P.A., Griffin J.H. High-density lipoprotein and the risk of recurrent venous thromboembolism. Circulation 2007, 115:1609-1614.
45. Navab M., Reddy S.T., Van Lenten B.J., Fogelman A.M. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat. Rev. Cardiol. 2011, 8:222-232.
46. Tang C., Liu Y., Kessler P.S., Vaughan A.M., Oram J.F. The macrophage cholesterol exporter ABCA1 functions as an anti-inflammatory receptor. J. Biol. Chem. 2009, 284:32336-32343.
47. Atzmon G., Gabriely I., Greiner W., Davidson D., Schechter C., Barzilai N. Plasma HDL levels highly correlate with cognitive function in exceptional longevity. J. Gerontol. A Biol. Sci. Med. Sci. 2002, 57:M712-M715.
48. Hyka N., Dayer J.M., Modoux C., Kohno T., Edwards C.K., Roux-Lombard P., Burger D. Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 2001, 97:2381-2389.
49. Yin K., Deng X., Mo Z.C., Zhao G.J., Jiang J., Cui L.B., Tan C.Z., Wen G.B., Fu Y., Tang C.K. Tristetraprolin-dependent post-transcriptional regulation of inflammatory cytokine mRNA expression by apolipoprotein A-I: role of ATP-binding membrane cassette transporter A1 and signal transducer and activator of transcription 3. J. Biol. Chem. 2011, 286:13834-13845.
50. Plump A.S., Azrolan N., Odaka H., Wu L., Jiang X., Tall A., Eisenberg S., Breslow J.L. ApoA-I knockout mice: characterization of HDL metabolism in homozygotes and identification of a post-RNA mechanism of apoA-I up-regulation in heterozygotes. J. Lipid Res. 1997, 38:1033-1047.
51. Deakin S., Moren X., James R.W. Very low density lipoproteins provide a vector for secretion of paraoxonase-1 from cells. Atherosclerosis 2005, 179:17-25.
52. Schwahn B.C., Chen Z., Laryea M.D., Wendel U., Lussier-Cacan S., Genest J., Mar M.H., Zeisel S.H., Castro C., Garrow T., Rozen R. Homocysteine-betaine interactions in a murine model of 5,10-methylenetetrahydrofolate reductase deficiency. FASEB J. 2003, 17:512-514.
53. Velez-Carrasco W., Merkel M., Twiss C.O., Smith J.D. Dietary methionine effects on plasma homocysteine and HDL metabolism in mice. J. Nutr. Biochem. 2008, 19:362-370.
54. Maclean K.N., Gaustadnes M., Oliveriusova J., Janosik M., Kraus E., Kozich V., Kery V., Skovby F., Rudiger N., Ingerslev J., Stabler S.P., Allen R.H., Kraus J.P. High homocysteine and thrombosis without connective tissue disorders are associated with a novel class of cystathionine beta-synthase (CBS) mutations. Hum. Mutat. 2002, 19:641-655.
55. Poynard T., Abella A., Pignon J.P., Naveau S., Leluc R., Chaput J.C. Apolipoprotein AI and alcoholic liver disease. Hepatology 1986, 6:1391-1395.
56. Mathurin P., Vidaud D., Vidaud M., Bedossa P., Paradis V., Ratziu V., Chaput J.C., Poynard T. Quantification of apolipoprotein A-I and B messenger RNA in heavy drinkers according to liver disease. Hepatology 1996, 23:44-51.
57. Yang F., Yin Y., Wang F., Zhang L., Wang Y., Sun S. An altered pattern of liver apolipoprotein A-I isoforms is implicated in male chronic hepatitis B progression. J. Proteome Res. 2010, 9:134-143.
58. Rowell J., Thompson A.J., Guyton J.R., Lao X.Q., McHutchison J.G., McCarthy J.J., Patel K. Serum apolipoprotein C-III is independently associated with chronic hepatitis C infection and advanced fibrosis. Hepatol. Int. 2012, 6:475-481.
59. Lieber C.S. Role of oxidative stress and antioxidant therapy in alcoholic and nonalcoholic liver diseases. Adv. Pharmacol. 1997, 38:601-628.
60. Ronis M.J., Butura A., Sampey B.P., Shankar K., Prior R.L., Korourian S., Albano E., Ingelman-Sundberg M., Petersen D.R., Badger T.M. Effects of N-acetylcysteine on ethanol-induced hepatotoxicity in rats fed via total enteral nutrition. Free Radic. Biol. Med. 2005, 39:619-630.
61. Ronis M.J., Hennings L., Stewart B., Basnakian A.G., Apostolov E.O., Albano E., Badger T.M., Petersen D.R. Effects of long-term ethanol administration in a rat total enteral nutrition model of alcoholic liver disease. Am. J. Physiol. Gastrointest. Liver Physiol. 2011, 300:G109-119.
62. Bruns H., Watanpour I., Gebhard M.M., Flechtenmacher C., Galli U., Schulze-Bergkamen H., Zorn M., Buchler M.W., Schemmer P. Glycine and taurine equally prevent fatty livers from Kupffer cell-dependent injury: an in vivo microscopy study. Microcirculation 2011, 18:205-213.
63. Li W.H., Tanimura M., Luo C.C., Datta S., Chan L. The apolipoprotein multigene family: biosynthesis, structure, structure-function relationships, and evolution. J. Lipid Res. 1988, 29:245-271.
64. Tang C., Vaughan A.M., Anantharamaiah G.M., Oram J.F. Janus kinase 2 modulates the lipid-removing but not protein-stabilizing interactions of amphipathic helices with ABCA1. J. Lipid Res. 2006, 47:107-114.
65. Ou J., Ou Z., Jones D.W., Holzhauer S., Hatoum O.A., Ackerman A.W., Weihrauch D.W., Gutterman D.D., Guice K., Oldham K.T., Hillery C.A., Pritchard K.A. L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation 2003, 107:2337-2341.
66. Ou J., Wang J., Xu H., Ou Z., Sorci-Thomas M.G., Jones D.W., Signorino P., Densmore J.C., Kaul S., Oldham K.T., Pritchard K.A. Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet. Circ. Res. 2005, 97:1190-1197.
67. Navab M., Anantharamaiah G.M., Hama S., Hough G., Reddy S.T., Frank J.S., Garber D.W., Handattu S., Fogelman A.M. D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1426-1432.
68. Navab M., Anantharamaiah G.M., Reddy S.T., Hama S., Hough G., Grijalva V.R., Yu N., Ansell B.J., Datta G., Garber D.W., Fogelman A.M. Apolipoprotein A-I mimetic peptides. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1325-1331.
69. Handattu S.P., Garber D.W., Monroe C.E., van Groen T., Kadish I., Nayyar G., Cao D., Palgunachari M.N., Li L., Anantharamaiah G.M. Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease. Neurobiol. Dis. 2009, 34:525-534.
70. Buga G.M., Frank J.S., Mottino G.A., Hendizadeh M., Hakhamian A., Tillisch J.H., Reddy S.T., Navab M., Anantharamaiah G.M., Ignarro L.J., Fogelman A.M. D-4F decreases brain arteriole inflammation and improves cognitive performance in LDL receptor-null mice on a Western diet. J. Lipid Res. 2006, 47:2148-2160.